ROFAST 40mg Price

Overview

Welcome to Dwaey, specifically on ROFAST 40mg Tablets/Film-coated page.
This medicine contains an important and useful components, as it consists of Rosuvastatin .
ROFAST 40mg is available in the market in concentration 40 mg/Tablet and in the form of Tablets/Film-coated.

AUROBINDO PHARMA FZ LLC is the producer of ROFAST 40mg and it is imported from UAE, The most popular alternatives of ROFAST 40mg are listed downward .

Mode Of Action

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. It increases the number of hepatic LDL receptors on the cell surface, enhancing uptake and catabolism of LDL. It also decreases apolipoprotein B, triglycerides and increases HDL.

Indication

• Hyperlipidaemias
• Primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia)
• mixed dyslipidaemia
• homozygous familial hypercholesterolaemia
• Stroke prevention

Precaution

Patients w/ predisposing factors for myopathy (e.g. untreated hypothyroidism, renal impairment), history of chronic liver disease and alcoholism. Monitoring Parameters Monitor creatine kinase (CK) periodically and LFT. Discontinue treatment if there is significant or persistent increase in CK levels, serum aminotransferase levels or evidence of myopathy. Lactation Contraindicated

Side Effects

• >10% Myalgia (3-13%) 1-10% Arthralgia (10%)
• Diabetes mellitus
• new onset (3%)
• Pharyngitis (9%)
• Headache (6%)
• Asthenia (up to 5%)
• Dizziness (4%)
• CPK increased (3%)
• Nausea (3%)
• Abdominal pain (2%)
• ALT increased (2%)
• Constipation (2%)
• Flulike illness (2%)
• UTI (2%) <1% Jaundice
• Myopathy
• Rhabdomyolysis Potentially Fatal: Rhabdomyolysis with acute renal failure.

Contra indication

Severe renal impairment, active liver disease, unexplained persistent elevations of serum transaminases; hypersensitivity. Pregnancy, lactation.

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.